“Global Liquid Biopsy market set to grow to $4.9bn by 2024” says new Visiongain report

04 December 2019
Pharma

Visiongain has launched a new pharma report Liquid Biopsy Market: Instruments, Kits and Reagents, Services, Blood Sample, Urine Sample, Circulating Tumour Cell (CTC), Circulating Tumour DNA (ctDNA), Exosomes, Breast Cancer, Colorectal Cancer, Liver Cancer, Lung Cancer, Prostate Cancer, Hospitals, Diagnostic Laboratories, Academic Institutions and Cancer Research Centres.

In the past three decades, diagnostic technology has witnessed tremendous advances across all of its branches. Liquid biopsy is a minimally invasive and precise alternative to the surgical biopsies, as it can determine the tumour information through blood samples. This technique allows physicians and surgeons to detect and treat cancer at an early stage.

The lead analyst of the report commented "The main drivers for the growth include technological advancements such as development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies. Moreover, rising number of pre-screening programs for cancer detection using liquid biopsy are expected to provide new market opportunities to the key players in the near future."

Leading companies featured in the report include Abbott, Beckman Coulter, Biocept, Inc., Bio-Rad Laboratories, Biotime, Caris Lifesciences, F. Hoffman-La Roche and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Ophthalmic Devices Market Report 2022-2032

The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.

19 April 2022

Read

Visiongain Publishes Vaccine Contract Manufacturing Market Report 2022-2032

The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet

13 April 2022

Read

Visiongain Publishes Pharmaceutical Contract Manufacturing Market Report 2022-2032

The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.

13 April 2022

Read

Visiongain Publishes Vaccine Sales Market Report 2022-2032

Rising epidemic potential, a growing emphasis on therapeutic vaccines, and new markets are projected to provide considerable growth prospects for vaccine providers.

30 March 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever